Related Experiment Video

Updated: Apr 26, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K

RNA interference: a promising therapy for gastric cancer

Aledson Vitor Felipe1, Juliana Oliveira, Paula Yun Joo Chang

  • 1Department of Medicine, Gastroenterology Division, Federal University of Sao Paulo, Sao Paulo, Brazil

Asian Pacific Journal of Cancer Prevention : APJCP
|August 2, 2014
PubMed

Insights

Gastric cancer (GC) is difficult to treat when metastatic. RNA-interference (RNAi) offers a promising epigenetic therapy by regulating oncogenes, potentially preventing GC recurrence and improving treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Gastric cancer (GC) is a leading cause of cancer-related mortality, particularly in its metastatic stages.
  • Early detection and effective treatment strategies are crucial for improving patient outcomes.
  • Current therapeutic options for advanced GC are limited, highlighting the need for novel approaches.

Purpose of the Study:

  • To review recent advances in RNA-interference (RNAi) as a therapeutic strategy for gastric cancer.
  • To explore the potential of RNAi in targeting oncogenes involved in gastric carcinogenesis.
  • To discuss RNAi's role as a promising epigenetic approach for GC treatment and prevention.

Main Methods:

  • This review synthesizes current research on RNA-interference (RNAi) mechanisms.
  • It examines studies investigating RNAi's efficacy in preclinical models of gastric cancer.
  • The review focuses on the application of RNAi for regulating oncogene expression in GC.

Main Results:

  • RNA-interference (RNAi) demonstrates significant potential in downregulating oncogenes crucial for gastric cancer development.
  • Epigenetic modulation via RNAi offers a novel therapeutic avenue for controlling GC progression.
  • Early findings suggest RNAi-based therapies could be effective in preventing GC recurrence.

Conclusions:

  • RNA-interference (RNAi) represents a promising biomolecular mechanism for gastric cancer therapy.
  • Targeting oncogenes through RNAi offers a novel epigenetic strategy for GC treatment.
  • Further research into RNAi-based interventions is warranted to combat gastric cancer effectively.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

6.5K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

9.1K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
816
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
24.3K
RNA Interference01:23

RNA Interference

6.4K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
798